ArticleJournal of gastrointestinal oncology2025
ISM2 as a prognostic biomarker and mediator of immune infiltration in colorectal cancer: evidence from bioinformatics and experimental analysis.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is a significant global health concern due to its high incidence and increasing prevalence among younger individuals. The identification of reliable biomarkers is essential for improving diagnostic accuracy and optimizing therapeutic strategies. Isthmin 2 (ISM2), a member of the Isthmin protein family, is expressed in multiple tissues, but its specific role in tumorigenesis and cancer progression remains poorly understood. Aberrant ISM2 expression has been detected in several malignancies, suggesting its potential involvement in cancer biology. Consequently, exploring the role of ISM2 in CRC is of great significance. This study aimed to explore the role of ISM2 in CRC, including its expression patterns, clinical significance, association with immune infiltration, and functional mechanisms. Methods: RNA transcriptome sequencing data and clinical data from 698 patients with CRC were retrieved from The Cancer Genome Atlas (TCGA) database to evaluate associations between ISM2 expression and clinicopathological parameters. Data were analyzed and visualized using R software, incorporating multiple databases such as TIMER. In parallel, Results: Bioinformatics analysis revealed that ISM2 was significantly elevated in CRC tissues compared to normal tissues and was differentially expressed across multiple tumor types. ISM2 demonstrated potential as a biomarker for distinguishing tumor tissues from non-tumor tissues and was associated with clinicopathological parameters, including TUMOR-NODE-METASTASIs (TNM) staging. Elevated ISM2 expression correlated with poorer overall survival (OS) outcomes. Additionally, ISM2 expression was inversely correlated with the presence of immune cells, particularly with CD8 Conclusions: ISM2 is overexpressed in CRC and is associated with clinicopathological features, prognosis, and immune infiltration. It holds potential as a prognostic biomarker; however, further research is needed to elucidate its underlying mechanisms and clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.